Toll-like-receptor-agonists - Pipeline Insight, 2024

This “Toll-like-receptor-agonists - Pipeline Insight, 2024” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Toll-like-receptor-agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Toll-like-receptor-agonists Understanding

Toll-like-receptor-agonists: Overview

TLR agonists play a fundamental role in activating innate and adaptive immune responses. The engagement of specific TLRs on cancer cells can impact tumor growth by various mechanisms, including inducing apoptosis and potentiating the effects of chemotherapy. Various TLRs have been reported to be expressed on a multitude of cancer types. TLR3 and TLR5 show the most promise for eliciting direct antitumor effects, whereas TLR4, -7, -8, and -9 display primarily protumor properties when stimulated on tumor cells. The use of multi-TLR agonists to induce potent antitumor responses remains a promising topic of research despite limited clinical evidence supporting the use of systemic TLR agonists as monotherapies.

Toll-like-receptor-agonists - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Toll-like-receptor-agonists pipeline landscape is provided which includes the disease overview and Toll-like-receptor-agonists treatment guidelines. The assessment part of the report embraces, in depth Toll-like-receptor-agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Toll-like-receptor-agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Toll-like-receptor-agonists R&D. The therapies under development are focused on novel approaches to treat/improve Toll-like-receptor-agonists.

Toll-like-receptor-agonists Emerging Drugs Chapters

This segment of the Toll-like-receptor-agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Toll-like-receptor-agonists Emerging Drugs

Cobitolimod: InDex Pharmaceuticals Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod met the primary endpoint in the Phase IIb study CONDUCT and demonstrated an outstanding combination of efficacy and safety. In March 2021, InDex Pharmaceuticals announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the Phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.

Tilsotolimod: Idera Pharmaceuticals Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Intratumoral injection of tilsotolimod has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation. Tilsotolimod has received both Fast Track designation and Orphan Drug designation from the FDA and is being evaluated in multiple tumor types and in combination with multiple checkpoint inhibitors. In March 2021, Idera Pharmaceuticals announced that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR).

Toll-like-receptor-agonists: Therapeutic Assessment

This segment of the report provides insights about the different Toll-like-receptor-agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Toll-like-receptor-agonists

There are approx. 35+ key companies which are developing the therapies for Toll-like-receptor-agonists. The companies which have their Toll-like-receptor-agonists drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

Phases

This report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Toll-like-receptor-agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Toll-like-receptor-agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Toll-like-receptor-agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-like-receptor-agonists drugs.

Toll-like-receptor-agonists Report Insights

• Toll-like-receptor-agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Toll-like-receptor-agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Toll-like-receptor-agonists drugs?
• How many Toll-like-receptor-agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Toll-like-receptor-agonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Toll-like-receptor-agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Toll-like-receptor-agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• InDex Pharmaceuticals
• Mologen
• Idera Pharmaceuticals
• Exicure
• Birdie Biopharmaceuticals/ Seven and Eight Biopharmaceuticals

Key Products

• Cobitolimod
• Lefitolimod
• Tilsotolimod
• Cavrotolimod
• BDB-001
• BDB-030
• BDB-018

This product will be delivered within 2 business days.